A report of three patients treated with immunocell therapy with imatinib mesylate

Anticancer Research

Volumn 24, Issue 5 C, 2004, Pages 3303-3309

  Kaneko, Toru ^a   Goto, Shigenori ^b   Kushima, Yoshiaki ^c   Miyamoto, Yoju ^a   Eriguchi, Masazumi ^a   Nieda, Mie ^d   Egawa, Koji ^d  

^a Shin yokohama Medical Clinic   (Japan)

^b Seta Clinic   (Japan)

^c Ryutoku kai Med Corp Tsuruta Hosp   (Japan)

^d Medinet Medical Institute   (Japan)

Author keywords

GIST; Imatinib mesylate; Immunocell therapy; Molecularly targeted therapy; Ph(+)ALL

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMATINIB; INTERLEUKIN 4; RECOMBINANT INTERLEUKIN 2;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CASE REPORT; CONFERENCE PAPER; DRUG EFFICACY; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE TARGETING; GROWTH INHIBITION; HUMAN; IMMUNOCELL THERAPY; MALE; MOLECULARLY TARGETED THERAPY; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH;

AGED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; STROMAL CELLS;

EID: 6344226338     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (31)

1. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE and Rubin JT: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889-897, 1987.
2. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G and Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4: 328-332, 1998.
3. Goto S, Shirotani N, Hatakeyama M, Tagami C, Arakawa H, Kuwata E, Noguchi K and Egawa K: Clinical benefit of non-toxic therapy in patients with advanced cancer (opinion). Anticancer Res 22: 2461-2464, 2002.
4. Komatsu T, Yamauchi K, Furukawa T and Obata H: Transcatheter arterial injection of autologous lymphokine-activated killer (LAK) cells into patients with liver cancers. J Clin Immunol 10: 167-174, 1990.
5. Haruta I, Yamauchi K, Aruga A, Komatsu T, Takasaki K, Hayashi N and Hanyu F: Analytical study of the clinical response to two distinct adoptive immunotherapies for advanced hepatocellular carcinoma: comparison between LAK cell and CTL therapy. J Immunother 19: 218-223, 1996.
6. Ebina T, Ogama N, Shimanuki H, Kubota T and Isono N: Life-prolonging effect of immunocell BAK (BRM-activated killer) therapy for advanced solid cancer patients: prognostic significance of serum immunosuppressive acidic protein levels Cancer Immunol Immunother 52: 555-560, 2003.
7. Steis RG, Urba WJ, Vandermolen LA, Bookman MA, Smith JW, Clark JW, Miller RL, Crum ED, Beckner SK, McKnight JE, Ozols RF, Stevenson HC, Young RC and Long DL: Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity. J Clin Oncol 8: 1618-1629, 1990.
8. Gomez GG, Hutchinson RB and Kruse CA: Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer. Cancer Treat Rev 27: 375-402, 2001.
9. Gold JE, Malamud SC, LaRosa F, Seder R and Osband ME: Adoptive chemoimmunotherapy for the treatment of relapsed and refractory solid tumors using ex vivo activated memory T cells (Autolymphocyte therapy) and cyclophosphamide. J Immunol 13: 213-221, 1993.
10. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP and Baselga: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21: 2237-46, 2003.
11. Rowley JD: Letter: A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 243: 290-293, 1973.
12. Shtivelman E, Lifshtz B, Gale RP and Canaani E: Fused transcript of abl and bcr genes in chronic myelogenous leukemia. Nature 315: 550-554, 1985.
13. Lugo TG, Pendergast AM, Muller AJ and Witte ON: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247: 1079-1082, 1990.
14. Konopka TG, Watanabe SM and Witte ON: An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine protein kinase activity. Cell 37: 1035-1042, 1984.
15. Nieda M, Nicol A, Kikuchi A, Kashiwase K, Taylor K, Suzuki K, Tadokoro K and Juji T: Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia. Blood 91: 977-983, 1998.
16. Tanaka Y, Takahashi T, Nieda M, Masuda S, Kashiwase K, Ogawa S, Chiba S, Juji T and Hirai H: Generation of Fas-independent CD4+ cytotoxic T-cell clone specific for p190 minor bcr-abl fusion peptide. Leuk Res 26: 317-321, 2002.
17. Goldman J.M and Melo J.V: Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Eng J Med 344: 1084-1086, 2001.
18. Druker BJ, Tamura S, Buchdunger E, Ohno S, Serai GM, Fanning S, Zimmermann J and Lydon NB: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Med 2: 561-566, 1996.
19. Hernandez-Boluda JC and Cervantes F: Imatinib Mesylate (Gleevec®/Glivec®): A new therapy for chronic myeloid leukemia and other malignancies. Drugs of Today 38(9): 601-613, 2002.
20. Druker, BJ, Sawyers, CL, Kantarjian, H, Resta DJ, Reese SF, Ford JM, Capdeville R and Talpaz M: Activity of a specific inhibitor of the Bcr/Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344: 1038-1042, 2001.
21. Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, Shan J, Faderl S, Garcia-Manero G, Thomas DA, Resta D and Talpaz M: Imatinib mesylate(STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 99: 3547-3553, 2002.
22. Thomas DA, Cortes J, Giles FJ, Faderl S, O'Brien S, Rios MB, Issa JP, Garcia-Manero G, Koller C, Capdeville R, Talpaz M and Kantarjian HM: Combination of hyper-CVAD with imatinib mesylate(STI571) for Philadelphia (Ph)-positive adult acute lymphoblastic leukemia(ALL) or chronic myelogenous leukemia in lymphoid blast phase (CML-LBP). Blood 98: 803a(abstract), 2001.
23. Ottman OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT, Tura S, Fischer T, Deininger MW, Schiffer CA, Baccarani M, Gratwohl A, Hochhaus A, Hoelzer D, Reese SF, Gathman I, Capdeville R and O'Brien SG: A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemia. Blood 100: 1965-1971, 2002.
24. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Tunio GM, Matsuzawa Y, Kanakura Y, Shinomura Y and Kitamura Y: Gain-of-function mutation of c-Kit in human gastrointestinal stromal tumors. Science 279: 577-580, 1998.
25. Nishida T, Hirota S, Taniguchi M, Hashimoto H, Isozaki K, Nakamura H, Kanakura Y, Tanaka T, Takabayashi A, Matsuda H and Kitamura Y: Familial gastrointestinal stromal tumors with germ line mutation of the KIT gene. Nat Genet 19: 323-324, 1998.
26. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CDM and Fletcher JA: PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299: 708-710, 2003.
27. Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y and Kitamura Y: Gain-of-function mutations of platelet-derived growth factor receptor alpha gene as another cause of human gastrointestinal stromal tumors. Gastroenterology 125: 660-667, 2003.
28. Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, Rahman A, Chen G, Staten A, Griebel D and Pazdur R: Approval summary: Imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 8: 3034-3038, 2002.
29. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts P, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CDM and Joensuu H: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-480, 2002.
30. Savage DG and Antman KH: Imatinib mesylate-A new oral targeted therapy. N Engl J Med 346: 683-693, 2002.
31. Mauro MJ, O'Dwyer M, Heinrich MC and Druker BJ: STI571: A paradigm of new agents for cancer therapeutics. J Clin Oncol 20: 325-334, 2002.